Abstract
Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Current Topics in Medicinal Chemistry
Title: Inhibitors and Modulators of β- and γ-Secretase
Volume: 6 Issue: 4
Author(s): Boris Schmidt, Stefanie Baumann, Hannes A. Braun and Gregor Larbig
Affiliation:
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Abstract: Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Export Options
About this article
Cite this article as:
Schmidt Boris, Baumann Stefanie, Braun A. Hannes and Larbig Gregor, Inhibitors and Modulators of β- and γ-Secretase, Current Topics in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/156802606776287027
DOI https://dx.doi.org/10.2174/156802606776287027 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders
Current Aging Science Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Role of Protein Phosphatase 2A in Alzheimers Disease
Current Alzheimer Research The Function and Integrity of the Neurovascular Unit Rests Upon the Integration of the Vascular and Inflammatory Cell Systems
Current Neurovascular Research Trait vs. State Markers for Schizophrenia: Identification and Characterization Through Visual Processes
Current Psychiatry Reviews Mitochondrial Dynamics and Proteins Related to Neurodegenerative Diseases
Current Protein & Peptide Science Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Reduced Alzheimer’s Disease Pathology by St. John’s Wort Treatment is Independent of Hyperforin and Facilitated by ABCC1 and Microglia Activation in Mice
Current Alzheimer Research Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels
Current Alzheimer Research Catatonia: A Brief Update
Current Psychiatry Reviews Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry